Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Azoniaspiro Compound Xvii
2. Azoniaspiro(3 Alpha-benziloyloxynortropane-8,1'- Pyrrolidine) Chloride
3. Ceris
4. Spasmex
5. Spasmo-lyt
6. Spasmo-rhoival Tc
7. Spasmo-urgenin
8. Spasmo-urgenin Tc
9. Spasmolyt
10. Trospi
11. Uraplex
12. Uraton
1. 10405-02-4
2. Sanctura
3. Spasmex
4. Relaspium
5. Spasmo-lyt
6. Uraplex
7. Sanctura Xr
8. Regurin
9. Santura
10. Trospium Cl
11. Trospii Chloridum
12. Cloruro De Trospio
13. Spasmo 3
14. Chlorure De Trospium
15. Trospium (chloride)
16. Ip631
17. Spasmoplex
18. Ip-631
19. Trospium Chloride (sanctura)
20. 1e6682427e
21. Dsstox_cid_3724
22. Dsstox_rid_77166
23. Dsstox_gsid_23724
24. Keptan
25. Azoniaspiro Compound Xvii
26. Flotros
27. As Xvii
28. Rel-(1r,3r,5s)-3-(2-hydroxy-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,1'-pyrrolidin]-1'-ium Chloride
29. Cas-10405-02-4
30. Ncgc00167438-01
31. Ncgc00167438-02
32. Trospiumchlorid
33. Spasmed
34. Trofame
35. Trospikan
36. Trosec
37. Regurin Xl
38. Trospii Chloridum [inn-latin]
39. Cloruro De Trospio [inn-spanish]
40. Unii-1e6682427e
41. Chlorure De Trospium [inn-french]
42. [(1s,5r)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate;chloride
43. Einecs 233-875-4
44. Trospium Chloride [usan:usp:inn:ban:jan]
45. Schembl25785
46. Trospium Chloride [mi]
47. Trospium Chloride [inn]
48. Trospium Chloride [jan]
49. Chembl3084748
50. Schembl13836646
51. Trospium Chloride [usan]
52. Chebi:32270
53. Trospium Chloride [mart.]
54. Hms3656c16
55. Hms3884h08
56. Trospium Chloride [usp-rs]
57. Trospium Chloride [who-dd]
58. Bcp23426
59. Hy-b0461
60. Tox21_112442
61. 8-alpha-benziloyloxy-6,10-ethano-5-azoniaspiro(4.5)decane Chloride
62. Azoniaspiro(3-alpha-benziloyloxy-nortropan-8,1'-pyrrolidine)-chloride
63. Bdbm50540489
64. Mfcd00865254
65. S2549
66. Akos015833209
67. Tox21_112442_1
68. Ac-4235
69. Ccg-268976
70. Trospium Chloride [orange Book]
71. Trospium Chloride [ep Monograph]
72. Trospium Chloride [usp Monograph]
73. Bcp0726000291
74. Sw219146-1
75. T3305
76. I11574
77. A800884
78. W-108827
79. Q27252312
80. 3alpha-hydroxyspiro(1alphah,5alphah-nortropane-8,1'-pyrrolidinium) Chloride Benzilate
81. (1s,3r,5r)-3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-8lambda(5)-azaspiro[bicyclo[3.2.1]octane-8,1'-pyrrolidin]-8-ylium Chloride
82. [(1s,5r)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-oxidanyl-2,2-diphenyl-ethanoate Chloride
83. 2-hydroxy-2,2-diphenylacetic Acid [(1s,5r)-3-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]yl] Ester Chloride
84. 3.alpha.-hydroxy-spiro(1.alpha.h,5.alpha.h-nortropane-8,1'-pyrrolidinium) Chloride Benzilate
85. Rel-(1r,3r,5s)-3-(2-hydroxy-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,1'-pyrrolidin]-1'-iumchloride
86. Spiro (8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium), 3-((hydroxydiphenylacetyl)oxy)-, Chloride, (1alpha, 3beta, 5alpha)
87. Spiro(1-alpha-h,5-alpha-h-nortropane-8,1'-pyrrolidinium), 3-alpha-hydroxy-, Chloride, Benzilate
88. Spiro(8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium), 3-((hydroxydiphenylacetyl)oxy)-, Chloride, (1.alpha., 3.beta., 5.alpha.)
89. Spiro(8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium, 3-((hydroxydiphenylacetyl)oxy)-, Chloride, (1alpha,3beta,5alpha)-
Molecular Weight | 428.0 g/mol |
---|---|
Molecular Formula | C25H30ClNO3 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 5 |
Exact Mass | 427.1914215 g/mol |
Monoisotopic Mass | 427.1914215 g/mol |
Topological Polar Surface Area | 46.5 Ų |
Heavy Atom Count | 30 |
Formal Charge | 0 |
Complexity | 553 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 6 | |
---|---|
Drug Name | Sanctura |
Drug Label | SANCTURA XR is an extended-release formulation of trospium chloride, a quaternary ammonium compound with the chemical name of Spiro [8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-[(hydroxydiphenylacetyl)oxy]-, chloride, (1, 3, 5). The e... |
Active Ingredient | Trospium chloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 20mg |
Market Status | Prescription |
Company | Allergan |
2 of 6 | |
---|---|
Drug Name | Sanctura xr |
Drug Label | SANCTURA XR is an extended-release formulation of trospium chloride, a quaternary ammonium compound with the chemical name of Spiro [8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-[(hydroxydiphenylacetyl)oxy]-, chloride, (1, 3, 5). The e... |
Active Ingredient | Trospium chloride |
Dosage Form | Capsule, extended release |
Route | Oral |
Strength | 60mg |
Market Status | Prescription |
Company | Allergan |
3 of 6 | |
---|---|
Drug Name | Trospium chloride |
PubMed Health | Trospium (By mouth) |
Drug Classes | Urinary Antispasmodic |
Drug Label | Trospium Chloride Extended-Release Capsules are an extended-release formulation of trospium chloride, a quaternary ammonium compound with the chemical name of Spiro [8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-[(hydroxydiphenylacetyl)oxy]-, c |
Active Ingredient | Trospium chloride |
Dosage Form | Tablet; Capsule, extended release |
Route | Oral |
Strength | 60mg; 20mg |
Market Status | Prescription |
Company | Actavis Labs Fl; Apotex; Glenmark Generics; Paddock |
4 of 6 | |
---|---|
Drug Name | Sanctura |
Drug Label | SANCTURA XR is an extended-release formulation of trospium chloride, a quaternary ammonium compound with the chemical name of Spiro [8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-[(hydroxydiphenylacetyl)oxy]-, chloride, (1, 3, 5). The e... |
Active Ingredient | Trospium chloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 20mg |
Market Status | Prescription |
Company | Allergan |
5 of 6 | |
---|---|
Drug Name | Sanctura xr |
Drug Label | SANCTURA XR is an extended-release formulation of trospium chloride, a quaternary ammonium compound with the chemical name of Spiro [8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-[(hydroxydiphenylacetyl)oxy]-, chloride, (1, 3, 5). The e... |
Active Ingredient | Trospium chloride |
Dosage Form | Capsule, extended release |
Route | Oral |
Strength | 60mg |
Market Status | Prescription |
Company | Allergan |
6 of 6 | |
---|---|
Drug Name | Trospium chloride |
PubMed Health | Trospium (By mouth) |
Drug Classes | Urinary Antispasmodic |
Drug Label | Trospium Chloride Extended-Release Capsules are an extended-release formulation of trospium chloride, a quaternary ammonium compound with the chemical name of Spiro [8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-[(hydroxydiphenylacetyl)oxy]-, c |
Active Ingredient | Trospium chloride |
Dosage Form | Tablet; Capsule, extended release |
Route | Oral |
Strength | 60mg; 20mg |
Market Status | Prescription |
Company | Actavis Labs Fl; Apotex; Glenmark Generics; Paddock |
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)
Urological Agents
Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)
Parasympatholytics
Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Trospium Chloride is a muscarinic antagonist it's generic has been approved for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Lead Product(s): Trospium Chloride
Therapeutic Area: Urology Brand Name: Sanctura-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2020
Lead Product(s) : Trospium Chloride
Therapeutic Area : Urology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Granules India Limited announces approval of Trospium Chloride ER Capsules, 60 mg
Details : Trospium Chloride is a muscarinic antagonist it's generic has been approved for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Brand Name : Sanctura-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 24, 2020
Details:
KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2024
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zai Lab Reports Positive Phase 3 Results for KarXT in Treating Schizophrenia
Details : KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia.
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 29, 2024
Details:
KarXT (xanomeline-trospium) is an investigational oral muscarinic agonist targeting psychiatric and neurological conditions like schizophrenia and Alzheimer’s psychosis.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2024
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Bristol Myers Presents New Long-Term Efficacy Data from EMERGENT-4 Trial
Details : KarXT (xanomeline-trospium) is an investigational oral muscarinic agonist targeting psychiatric and neurological conditions like schizophrenia and Alzheimer’s psychosis.
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 06, 2024
Details:
BMS acquires KarXT (xanomeline-trospium), an M1/M4 receptor agonist, for treating schizophrenia, enhancing its development.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Bristol Myers Squibb
Deal Size: $14,000.0 million Upfront Cash: $14,000.0 million
Deal Type: Acquisition March 18, 2024
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Bristol Myers Squibb
Deal Size : $14,000.0 million
Deal Type : Acquisition
Bristol Myers Squibb Completes Acquisition Of Karuna Therapeutics for $14 Billion
Details : BMS acquires KarXT (xanomeline-trospium), an M1/M4 receptor agonist, for treating schizophrenia, enhancing its development.
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : $14,000.0 million
March 18, 2024
Details:
Through the acquisition, BMS will enhance the development of KarXT (xanomeline-trospium), an antipsychotic with a novel mechanism of being a first-in-class M1 / M4 muscarinic receptor agonist, with differentiated efficacy and safety for treating schizophrenia in adults.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Bristol Myers Squibb
Deal Size: $14,000.0 million Upfront Cash: $14,000.0 million
Deal Type: Acquisition December 22, 2023
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Bristol Myers Squibb
Deal Size : $14,000.0 million
Deal Type : Acquisition
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
Details : Through the acquisition, BMS will enhance the development of KarXT (xanomeline-trospium), an antipsychotic with a novel mechanism of being a first-in-class M1 / M4 muscarinic receptor agonist, with differentiated efficacy and safety for treating schizoph...
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : $14,000.0 million
December 22, 2023
Details:
KarXT (xanomeline and trospium chloride) is an M1/M4 receptor Agonist small molecule drug delivered orally in capsule form for the treatment of Schizophrenia.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KarXT (xanomeline and trospium chloride) is an M1/M4 receptor Agonist small molecule drug delivered orally in capsule form for the treatment of Schizophrenia.
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 29, 2023
Details:
KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2023
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 17, 2023
Details:
KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2023
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 16, 2023
Details:
KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Karuna Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Karuna Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia
Details : KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 28, 2023
Details:
The proceedings will be used to fund Karuna's ongoing and planned clinical trials of KarXT (xanomeline), to support the potential commercialization of KarXT for psychosis in schizophrenia, to support and expand company's pipeline of clinical and preclinical programs.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Goldman Sachs & Co. LLC
Deal Size: $460.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 24, 2023
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Goldman Sachs & Co. LLC
Deal Size : $460.0 million
Deal Type : Public Offering
Details : The proceedings will be used to fund Karuna's ongoing and planned clinical trials of KarXT (xanomeline), to support the potential commercialization of KarXT for psychosis in schizophrenia, to support and expand company's pipeline of clinical and preclini...
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 24, 2023
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?